Get started
CytoDyn Inc.CytoDyn Inc.CytoDyn Inc.

CytoDyn Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

CYDY trade ideas

How will CYDY fractal resolve anticipated FDA approval for COVIDThis week CYDY has reached the mid-$4 range predicted in April to complete the fractal growth channel since late 2019 lows at $.26. Since April, we know Cytodyn has treated at least 80 COVID patients in its Phase II mild-moderate trial, 70 in its Phase III severe trial and at least 75 EIND emergency patients outside blind trials. We know from Dr. Bruce Patterson's paper preprint www.medrxiv.org that the blood work shows quick restoration of normal immune function for most emergency patients, and have many anecdotes of EIND patients who were stuck on ventilators or ECMO for weeks come off within a couple days of receiving Leronlimab. We even have good anecdotes on Youtube from blind trial patients: m.youtube.com All hints suggests FDA approval for COVID should be forthcoming once trial results are released in July, along with exchange uplisting and acceleration of trials in NASH, MS, Alzheimers and solid tumor cancers. More trial successes in these indications could fundamentally raise the stock price another 10x this year. Yet the fractal growth pattern of the past 6 months looks nominally complete this week at $4.50. How can this paradox resolve? Barring some unforeseen disaster, a steeper channel is called for in July-August: CYDY may go parabolic. When we look at the fractal microstructure of stocks that have gone parabolic like Amazon, bitcoin, palladium, 1995-2000 internet bubble, we find a parabolic envelope with linear channels of increasing slope inside, and relatively miniscule flat corrective waves. Inside the parabolic envelope, Wave III channel has a much steeper slope than wave I channel, and wave V is steeper yet again than wave III. Waves II and IV are mere shallow connectors from the upper parabolic envelope to the lower envelope. So instead of a typical 50% wave II correction down to .5*(4.57-0.26) + .26 = 2.46, wave II could be much shallower only hitting the mid $3's again before turning up towards double digits in a quick wave III upon COVID FDA approval. It's also possible that we still do see a normally deep wave II to $2.50 from some unexpected shocking delay or turn of events sufficient to scare out investors who have joined since April on glowing prospects. CYDY continues to be one of the most amazing speculation opportunities we've encountered. We use the fractal roadmap to scalp and manage the emotions of holding a large, long-term core position.
OTC:CYDYLong
by pythagoras
3
How will CYDY attack 2011 highs with COVID treatment results?Here's another possible fractal path for CYDY over coming weeks. It appears to be consolidating and basing in 2.76-3.2 zone ready for an attack on 3.57-3.65, then 3.83-4 and eventually the old 2011 all-time high around 4.4 (when there were WAY fewer outstanding shares!). This sort of stair-stepped march-up can be expected so long as trial results and partnering news continue to trickle out a few patients at a time over the next few weeks. However, keep in mind that a sudden FDA emergency approval or tweets by Trump about leronlimab could spike CYDY into 5-10 range instantaneously, bypassing these lazy zig-zags.
OTC:CYDYLong
by pythagoras
Fractal/Elliot suggests CYDY > $3.80 on Coronavirus news cycleThe super-hot bio-tech startup Cytodyn with their humanized monoclonal antibody Leronlamib has been on a tear up 1000% since November 2019 lows ($.26). The rally has been driven by many press releases: stabilized financing and marketing contracts, amazing results in their early cancer trials and now serendipitous immunological application to severe coronavirus patients. But despite the news-driven nature of the rally, price has been bouncing in fractal waves with usual structures expected by 100-year-old "Elliot wave" theory. Experienced fractal technicians can predict good profit-taking zones where price is likely to be driven or correct after each press release. www.cytodyn.com www.instagram.com According to fractal theory of market pricing, strongly trending stocks and indeces tend to move in nested 5-wave zig-zag channels. CYDY has been clearly following this behavior in its December uptrend, with 5 clear up waves into major wave I at $1.64 (we predicted $1.60) in January. As expected, 5 clear subwaves can be seen in waves 1, 3, and 5 of I, while the 2 and 4 corrective waves have less clear structure. Wave III into $3.50 on Monday was very fast -- driven by last Friday's press release on the first 4 severe coronavirus patient responses. Wave III had a huge gap and spike over the weekend that obscures any internal substructure. Wave IV appears to be a triangle that collapsed back to $1.90 Monday then back up to $3.40 this morning in 5 clear microwaves (try zooming on this week), then again collapsed back toward $2. This triangle consolidation bouncing between $2 and $3.40 may go on for a couple weeks until the next meaningful trial results drive wave V past $3.50. It's possible wave V goes to $5-10 on powerful enough news, but wave V heights are often about wave I height. Measured from the center of the wave IV triangle which we now assume to be (3.50+1.90)/2=2.70, one can project a wave V top price of around 2.70 + (1.64-.26) = 4.08 (or higher). At that point we would expect another large correction back toward $2 or possibly even filling the gap at $1.40, not because of anything particularly bad happening with CYDY but just because of typical investor psychology and volatility after 2000% gains. There are fascinating relationships between these expected fractal oscillations and Nader's press releases. Several times we've seen the bigger corrections after a conference call or press release that simply suggests investors will need to wait a few weeks more for major news. This gives shorts and market makers a chance to drive down price without risking another huge gap up on amazing news the next day. Hopefully wave V will turn out to just be a larger ONE, the big correction TWO on its way to a larger FIVE in the $20-50 range as FDA approves leronlamib for HIV, cancer, etc and high volume sales commence.
OTC:CYDYLong
by pythagoras
CYDY headed toward 1.60 next for wave 5 of I toward stratosphereCytodyn is a 9-year old biotech startup nearing FDA approval for Leronlamib, a humanized monoclonal antibody that's shown no side effects with over 800 AIDS patients through a Phase 3 HIV combo-therapy trial. But Leronlamib is also showing broad efficacy in early trials for HIV monotherapy, HIV prevention, blocking metastasis of many cancers, graft vs host disease, and fatty liver disease (NASH). It was tremendously undervalued until mid-December when it signed an $87 million HIV licensing and commercialization that has stabilized its financing and launched price in a strong up-channel. Submission of BLA application to FDA for HIV combo therapy is imminent in January, which should allow for FDA approval and first sales in 2020. Leronlamib has the potential to transform treatment of several major diseases. Disclosure: I am heavily long.
OTC:CYDYLong
by pythagoras
1
CYDY PT1RSI under 70, potential upside left. Enter a short position at 1.4180 or higher, cover at 1.1090 . You can trade the consolidation area highlighted by the yellow triangle, from 1.26-1.38 with very tight stops, as once the consolidation is broken, 1.090 is your next stop. Only high volume trades, min. 1k shares. (ps. If price fails to break fibo/consolidation/support at 1.3050 (unlikely), cover, take profits preemptively and wait for re-entry, price target remains unchanged.)
OTC:CYDYShort
by Cetan